Rindopepimut (CDX-110) with GM-CSF + Temozolomide + KLH
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma
Conditions
Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component
Trial Timeline
Nov 1, 2011 → Nov 1, 2016
NCT ID
NCT01480479About Rindopepimut (CDX-110) with GM-CSF + Temozolomide + KLH
Rindopepimut (CDX-110) with GM-CSF + Temozolomide + KLH is a phase 3 stage product being developed by Celldex Therapeutics for Glioblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01480479. Target conditions include Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01480479 | Phase 3 | Completed |
Competing Products
20 competing products in Glioblastoma